NCT05077280View on ClinicalTrials.gov

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2026

Conditions
Uveal Melanoma
Interventions
RADIATION

stereotactic body radiotherapy

Stereotactic Body radiotherapy will be given to 1-5 target metastases in 3 doses over 8 days or less. Each dose will be 15Gy for a total dose of 45GY

DRUG

Immunotherapy

Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years

Trial Locations (1)

94115

RECRUITING

California Pacific Medical Center Research Institute, San Francisco

Sponsors
All Listed Sponsors
lead

California Pacific Medical Center Research Institute

OTHER